Ticker Details
Verastem, Inc. Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
IPO Date:	February 1, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$491M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.17 | 3.39%
Avg Daily Range (30 D):	$0.20 | 3.50%
Avg Daily Range (90 D):	$0.23 | 3.42%

Institutional Daily Volume
Avg Daily Volume:	1.21M
Avg Daily Volume (30 D):	1.7M
Avg Daily Volume (90 D):	1.57M

Trade Size
Avg Trade Size (Sh.):	239
Avg Trade Size (Sh.) (30 D):	93
Avg Trade Size (Sh.) (90 D):	96

Institutional Trades
Total Institutional Trades:	888
Avg Institutional Trade:	$1.63M
Avg Institutional Trade (30 D):	$1.26M
Avg Institutional Trade (90 D):	$1.28M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.8M
Avg Closing Trade (30 D):	$1.34M
Avg Closing Trade (90 D):	$1.44M
Avg Closing Volume:	141.14K

News

Nov 12, 2025 @ 6:00 PM KRAS Inhibitors Market to Witness Explosive Growth... Source: Delveinsight

Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire

Mar 8, 2025 @ 12:33 PM Why the Global Cancer Market Could Surpass $900 Bi... Source: Prnewswire

Jul 24, 2024 @ 9:27 AM Why Enphase Energy Shares Are Trading Higher; Here... Source: Avi Kapoor

Jul 10, 2024 @ 6:51 PM Verastem, Inc. Investors: Company Investigated by ... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.02	$-.29	$-3.02
Diluted EPS	$-3.02	$-.29	$-3.02
Revenue	$30.91M	$17.54M	$30.91M
Gross Profit
Net Income / Loss	$-209.47M	$-32.92M	$-209.47M
Operating Income / Loss	$-170.13M	$-41.48M	$-170.13M
Cost of Revenue
Net Cash Flow	$116.17M	$67.28M	$116.17M
PE Ratio

Splits
Jun 01, 2023	1:12